These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 36581107

  • 21. Does Media Choice Matter When Evaluating the Performance of Hydroxypropyl Methylcellulose Acetate Succinate-Based Amorphous Solid Dispersions?
    Bapat P, Paul S, Thakral NK, Tseng YC, Taylor LS.
    Mol Pharm; 2023 Nov 06; 20(11):5714-5727. PubMed ID: 37751517
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability.
    Miller JM, Beig A, Carr RA, Spence JK, Dahan A.
    Mol Pharm; 2012 Jul 02; 9(7):2009-16. PubMed ID: 22632106
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Insight into Amorphous Solid Dispersion Performance by Coupled Dissolution and Membrane Mass Transfer Measurements.
    Hate SS, Reutzel-Edens SM, Taylor LS.
    Mol Pharm; 2019 Jan 07; 16(1):448-461. PubMed ID: 30521350
    [Abstract] [Full Text] [Related]

  • 26. Novel supercritical carbon dioxide impregnation technique for the production of amorphous solid drug dispersions: a comparison to hot melt extrusion.
    Potter C, Tian Y, Walker G, McCoy C, Hornsby P, Donnelly C, Jones DS, Andrews GP.
    Mol Pharm; 2015 May 04; 12(5):1377-90. PubMed ID: 25730138
    [Abstract] [Full Text] [Related]

  • 27. Design and scale-up of amorphous drug nanoparticles production via a one-step anhydrous continuous process.
    Jacobs E, Qian K, Pietsch VL, Richter M, Jones DS, Andrews GP, Tian Y.
    Int J Pharm; 2022 Nov 25; 628():122304. PubMed ID: 36265663
    [Abstract] [Full Text] [Related]

  • 28. Effects of Surfactants on Itraconazole-HPMCAS Solid Dispersion Prepared by Hot-Melt Extrusion I: Miscibility and Drug Release.
    Solanki NG, Lam K, Tahsin M, Gumaste SG, Shah AV, Serajuddin ATM.
    J Pharm Sci; 2019 Apr 25; 108(4):1453-1465. PubMed ID: 30395834
    [Abstract] [Full Text] [Related]

  • 29. Drug Release from Surfactant-Containing Amorphous Solid Dispersions: Mechanism and Role of Surfactant in Release Enhancement.
    Yang R, Zhang GGZ, Zemlyanov DY, Purohit HS, Taylor LS.
    Pharm Res; 2023 Dec 25; 40(12):2817-2845. PubMed ID: 37052841
    [Abstract] [Full Text] [Related]

  • 30. Release Mechanisms of Amorphous Solid Dispersions: Role of Drug-Polymer Phase Separation and Morphology.
    Yang R, Zhang GGZ, Zemlyanov DY, Purohit HS, Taylor LS.
    J Pharm Sci; 2023 Jan 25; 112(1):304-317. PubMed ID: 36306863
    [Abstract] [Full Text] [Related]

  • 31. Dissolution of Danazol Amorphous Solid Dispersions: Supersaturation and Phase Behavior as a Function of Drug Loading and Polymer Type.
    Jackson MJ, Kestur US, Hussain MA, Taylor LS.
    Mol Pharm; 2016 Jan 04; 13(1):223-31. PubMed ID: 26618718
    [Abstract] [Full Text] [Related]

  • 32. Congruent Release of Drug and Polymer from Amorphous Solid Dispersions: Insights into the Role of Drug-Polymer Hydrogen Bonding, Surface Crystallization, and Glass Transition.
    Saboo S, Kestur US, Flaherty DP, Taylor LS.
    Mol Pharm; 2020 Apr 06; 17(4):1261-1275. PubMed ID: 32134677
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Comparative study of the potential of poly(2-ethyl-2-oxazoline) as carrier in the formulation of amorphous solid dispersions of poorly soluble drugs.
    Boel E, Smeets A, Vergaelen M, De la Rosa VR, Hoogenboom R, Van den Mooter G.
    Eur J Pharm Biopharm; 2019 Nov 06; 144():79-90. PubMed ID: 31499162
    [Abstract] [Full Text] [Related]

  • 39. Enhanced oral delivery of celecoxib via the development of a supersaturable amorphous formulation utilising mesoporous silica and co-loaded HPMCAS.
    Lainé AL, Price D, Davis J, Roberts D, Hudson R, Back K, Bungay P, Flanagan N.
    Int J Pharm; 2016 Oct 15; 512(1):118-125. PubMed ID: 27543354
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.